S100P and chronic myelogenous leukemia, BCR-ABL1 positive: Within a set of n = 36 samples of CML patients in the late chronic phase and n = 23 samples of newly diagnosed chronic phase patients,17LASP1, S100P, SFN and CXCR4 mRNA were found to be expressed significantly lower (P < .05; marked by colour) in patients' samples not responding to imatinib therapy (Table 1).